Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14994200 | 0.87 | SMN1; SMN2 (0.59) | CPS1SMN1; SMN2AKR1C3AKR1C2MEN1 | |
| SCHEMBL27888628 | 0.85 | CDC25B (0.56) | CPS1AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL395640 | 0.85 | SMN1; SMN2 (0.59) | CPS1SMN1; SMN2AKR1C3AKR1C2MEN1 | |
| SCHEMBL531399 | 0.85 | ALDH1A1 (0.65) | CPS1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL29639738 | 0.85 | ALDH1A1 (0.65) | CPS1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL1555099 | 0.83 | CPS1 (0.61) | CPS1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL1554929 | 0.83 | CPS1 (0.61) | CPS1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL72082 | 0.83 | CPS1 (0.61) | CPS1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL15226106 | 0.83 | CPS1 (0.61) | CPS1NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL6692981 | 0.82 | ALDH1A1 (0.49) | CPS1AKR1C3AKR1C2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-118239832-A | Preparation method of 2-fluoro-4-methoxybenzoic acid | 台州凌峰生物科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| CN-116178685-A | LCP material with high clearing point and preparation method thereof | 宁夏清研高分子新材料有限公司 | 2023-05-30 | — | — | CN | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-110343070-A | A kind of Antitubulin and the preparation method and application thereof | 山东大学 | 2019-10-18 | — | — | CN | claimed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| CN-103958690-A | Method for controlling undesirable byproducts formation caused by contaminating organisms in the production of ethanol from syngas | COSKATA INC | 2014-07-30 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4713306-A1 | NOVEL TRACER FOR THE IN VIVO DETECTION OF THE AGGREGATION OF ALPHA-SYNUCLEIN | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999034790-A1 | GLYCINE TRANSPORT INHIBITORS | ALLELIX NEUROSCIENCE, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| US-3985891-A | CARDIOTONICS, ANTICOAGULANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | CPS1 2702/4885SMN1; SMN2 3838/4885AKR1C3 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.